S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.15 (-0.58%)
AAPL   169.60 (-1.37%)
MSFT   310.36 (-0.57%)
META   290.97 (-2.67%)
GOOGL   129.03 (+0.36%)
AMZN   125.05 (-0.74%)
TSLA   236.34 (-3.19%)
NVDA   418.22 (-0.21%)
NIO   8.36 (-0.59%)
BABA   85.69 (-0.26%)
AMD   97.07 (+1.16%)
T   14.83 (-1.26%)
F   12.29 (-1.13%)
MU   67.13 (-1.19%)
CGC   0.88 (-4.51%)
GE   110.41 (+0.44%)
DIS   79.46 (-0.74%)
AMC   7.67 (-3.03%)
PFE   32.03 (-1.14%)
PYPL   56.91 (-3.43%)
NFLX   376.81 (-0.64%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.15 (-0.58%)
AAPL   169.60 (-1.37%)
MSFT   310.36 (-0.57%)
META   290.97 (-2.67%)
GOOGL   129.03 (+0.36%)
AMZN   125.05 (-0.74%)
TSLA   236.34 (-3.19%)
NVDA   418.22 (-0.21%)
NIO   8.36 (-0.59%)
BABA   85.69 (-0.26%)
AMD   97.07 (+1.16%)
T   14.83 (-1.26%)
F   12.29 (-1.13%)
MU   67.13 (-1.19%)
CGC   0.88 (-4.51%)
GE   110.41 (+0.44%)
DIS   79.46 (-0.74%)
AMC   7.67 (-3.03%)
PFE   32.03 (-1.14%)
PYPL   56.91 (-3.43%)
NFLX   376.81 (-0.64%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.15 (-0.58%)
AAPL   169.60 (-1.37%)
MSFT   310.36 (-0.57%)
META   290.97 (-2.67%)
GOOGL   129.03 (+0.36%)
AMZN   125.05 (-0.74%)
TSLA   236.34 (-3.19%)
NVDA   418.22 (-0.21%)
NIO   8.36 (-0.59%)
BABA   85.69 (-0.26%)
AMD   97.07 (+1.16%)
T   14.83 (-1.26%)
F   12.29 (-1.13%)
MU   67.13 (-1.19%)
CGC   0.88 (-4.51%)
GE   110.41 (+0.44%)
DIS   79.46 (-0.74%)
AMC   7.67 (-3.03%)
PFE   32.03 (-1.14%)
PYPL   56.91 (-3.43%)
NFLX   376.81 (-0.64%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.15 (-0.58%)
AAPL   169.60 (-1.37%)
MSFT   310.36 (-0.57%)
META   290.97 (-2.67%)
GOOGL   129.03 (+0.36%)
AMZN   125.05 (-0.74%)
TSLA   236.34 (-3.19%)
NVDA   418.22 (-0.21%)
NIO   8.36 (-0.59%)
BABA   85.69 (-0.26%)
AMD   97.07 (+1.16%)
T   14.83 (-1.26%)
F   12.29 (-1.13%)
MU   67.13 (-1.19%)
CGC   0.88 (-4.51%)
GE   110.41 (+0.44%)
DIS   79.46 (-0.74%)
AMC   7.67 (-3.03%)
PFE   32.03 (-1.14%)
PYPL   56.91 (-3.43%)
NFLX   376.81 (-0.64%)
NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Forecast, Price & News

$0.08
0.00 (-2.35%)
(As of 02:01 PM ET)
Compare
Today's Range
$0.08
$0.09
50-Day Range
$0.09
$0.50
52-Week Range
$0.08
$2.42
Volume
16.26 million shs
Average Volume
1.27 million shs
Market Capitalization
$9.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

RVL Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
3,117.5% Upside
$2.50 Price Target
Short Interest
Healthy
3.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of RVL Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

634th out of 963 stocks

Pharmaceutical Preparations Industry

285th out of 451 stocks


RVLP stock logo

About RVL Pharmaceuticals (NASDAQ:RVLP) Stock

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVLP Price History

RVLP Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
RVL Pharmaceuticals (RVLP) Gets a Buy from H.C. Wainwright
RVLP: Second Quarter Results
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Q2 2023 RVL Pharmaceuticals PLC Earnings Call
RVLP: First Quarter Results
Q1 2023 RVL Pharmaceuticals PLC Earnings Call
RVLP: Selected for NewBeauty Award
See More Headlines
Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+2,841.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-51,690,000.00
Net Margins
-184.91%
Pretax Margin
-185.66%

Debt

Sales & Book Value

Annual Sales
$36.92 million
Book Value
$0.51 per share

Miscellaneous

Free Float
106,504,000
Market Cap
$9.47 million
Optionable
Optionable
Beta
1.15
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Brian A. Markison (Age 64)
    Chairman, Pres, CEO & Principal Financial Officer
    Comp: $525k
  • Mr. James D. Schaub (Age 41)
    Exec. VP & COO
    Comp: $367.2k
  • Mr. Christopher A. Klein (Age 58)
    Gen. Counsel & Sec.
    Comp: $367.2k
  • Mr. Michael J. DePetris (Age 46)
    Principal Accounting Officer
  • Mr. Jarret Miller
    Exec. VP of HR













RVLP Stock - Frequently Asked Questions

Should I buy or sell RVL Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVLP shares.
View RVLP analyst ratings
or view top-rated stocks.

What is RVL Pharmaceuticals' stock price forecast for 2023?

3 equities research analysts have issued twelve-month price objectives for RVL Pharmaceuticals' stock. Their RVLP share price forecasts range from $2.00 to $3.00. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 2,841.2% from the stock's current price.
View analysts price targets for RVLP
or view top-rated stocks among Wall Street analysts.

How have RVLP shares performed in 2023?

RVL Pharmaceuticals' stock was trading at $1.12 at the start of the year. Since then, RVLP stock has decreased by 92.4% and is now trading at $0.0850.
View the best growth stocks for 2023 here
.

When is RVL Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RVLP earnings forecast
.

How were RVL Pharmaceuticals' earnings last quarter?

RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). The firm earned $8.26 million during the quarter, compared to analyst estimates of $10.38 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 130.22% and a negative net margin of 184.91%.

What is RVL Pharmaceuticals' stock symbol?

RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP."

Who are RVL Pharmaceuticals' major shareholders?

RVL Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (1.52%), Worth Venture Partners LLC (0.28%) and Citadel Advisors LLC (0.00%).

How do I buy shares of RVL Pharmaceuticals?

Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RVL Pharmaceuticals' stock price today?

One share of RVLP stock can currently be purchased for approximately $0.09.

How much money does RVL Pharmaceuticals make?

RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $9.47 million and generates $36.92 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does RVL Pharmaceuticals have?

The company employs 125 workers across the globe.

How can I contact RVL Pharmaceuticals?

RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com.

This page (NASDAQ:RVLP) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -